» Articles » PMID: 24441042

Systems Level-based RNAi Screening by High Content Analysis Identifies UBR5 As a Regulator of Estrogen Receptor-α Protein Levels and Activity

Overview
Journal Oncogene
Date 2014 Jan 21
PMID 24441042
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Estrogen receptor-α (ERα) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ERα-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ERα protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ERα protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ERα target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ERα levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERα protein levels and transcriptional activity.

Citing Articles

E3 ubiquitin ligase UBR5 modulates circadian rhythm by facilitating the ubiquitination and degradation of the key clock transcription factor BMAL1.

Duan C, Li Y, Zhi H, Tian Y, Huang Z, Chen S Acta Pharmacol Sin. 2024; 45(9):1793-1808.

PMID: 38740904 PMC: 11336169. DOI: 10.1038/s41401-024-01290-z.


UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.

Tsai J, Aguirre J, Li Y, Brown J, Focht V, Kater L Mol Cell. 2023; 83(15):2753-2767.e10.

PMID: 37478846 PMC: 11134608. DOI: 10.1016/j.molcel.2023.06.028.


CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.

Tiwari P, Ko T, Dubey R, Chouhan M, Tsai L, Singh H Front Mol Biosci. 2023; 10:1214489.

PMID: 37469704 PMC: 10352522. DOI: 10.3389/fmolb.2023.1214489.


CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.

Karn V, Sandhya S, Hsu W, Parashar D, Singh H, Jha N Cancer Cell Int. 2022; 22(1):234.

PMID: 35879772 PMC: 9316746. DOI: 10.1186/s12935-022-02654-3.


UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced transcription in triple negative breast cancer.

Wu B, Song M, Dong Q, Xiang G, Li J, Ma X Theranostics. 2022; 12(11):5086-5102.

PMID: 35836797 PMC: 9274738. DOI: 10.7150/thno.74989.


References
1.
Ashcroft F, Newberg J, Jones E, Mikic I, Mancini M . High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes. Gene. 2011; 477(1-2):42-52. PMC: 3086628. DOI: 10.1016/j.gene.2011.01.009. View

2.
Fox E, Miller T, Balko J, Kuba M, Sanchez V, Smith R . A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011; 71(21):6773-84. PMC: 3206206. DOI: 10.1158/0008-5472.CAN-11-1295. View

3.
Clancy J, Henderson M, Russell A, Anderson D, Bova R, Campbell I . EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 2003; 22(32):5070-81. DOI: 10.1038/sj.onc.1206775. View

4.
Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D . Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011; 17(6):715-9. DOI: 10.1038/nm.2351. View

5.
Gonzalez-Arenas A, Hansberg-Pastor V, Hernandez-Hernandez O, Gonzalez-Garcia T, Henderson-Villalpando J, Lemus-Hernandez D . Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim Biophys Acta. 2011; 1823(2):379-86. DOI: 10.1016/j.bbamcr.2011.11.004. View